BRPI0915439A2 - composição tópica para o tratamento de ceratose actínica - Google Patents

composição tópica para o tratamento de ceratose actínica

Info

Publication number
BRPI0915439A2
BRPI0915439A2 BRPI0915439A BRPI0915439A BRPI0915439A2 BR PI0915439 A2 BRPI0915439 A2 BR PI0915439A2 BR PI0915439 A BRPI0915439 A BR PI0915439A BR PI0915439 A BRPI0915439 A BR PI0915439A BR PI0915439 A2 BRPI0915439 A2 BR PI0915439A2
Authority
BR
Brazil
Prior art keywords
treatment
topical composition
actinic keratosis
keratosis
actinic
Prior art date
Application number
BRPI0915439A
Other languages
English (en)
Inventor
Carmen Matthies
Christoph Willers
Henning Mallwitz
Klaus Treudler
Manfred Melzer
Original Assignee
Almirall Hermal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915439(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Hermal Gmbh filed Critical Almirall Hermal Gmbh
Publication of BRPI0915439A2 publication Critical patent/BRPI0915439A2/pt
Publication of BRPI0915439B1 publication Critical patent/BRPI0915439B1/pt
Publication of BRPI0915439B8 publication Critical patent/BRPI0915439B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915439A 2008-07-07 2009-06-29 composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição BRPI0915439B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis
EP08012237.7 2008-07-07
PCT/EP2009/004682 WO2010003568A1 (en) 2008-07-07 2009-06-29 Topical composition for the treatment of actinic keratosis

Publications (3)

Publication Number Publication Date
BRPI0915439A2 true BRPI0915439A2 (pt) 2015-11-10
BRPI0915439B1 BRPI0915439B1 (pt) 2019-10-08
BRPI0915439B8 BRPI0915439B8 (pt) 2021-05-25

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915439A BRPI0915439B8 (pt) 2008-07-07 2009-06-29 composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição

Country Status (32)

Country Link
US (1) US8569320B2 (pt)
EP (2) EP2143421A1 (pt)
JP (2) JP5654987B2 (pt)
KR (1) KR101689898B1 (pt)
CN (2) CN104825384A (pt)
AR (1) AR072685A1 (pt)
AU (1) AU2009267471B2 (pt)
BR (1) BRPI0915439B8 (pt)
CA (1) CA2729974A1 (pt)
CL (1) CL2010001642A1 (pt)
CO (1) CO6351710A2 (pt)
CY (1) CY1116111T1 (pt)
DK (1) DK2315581T3 (pt)
EA (1) EA019533B1 (pt)
EC (1) ECSP11010762A (pt)
ES (1) ES2532948T3 (pt)
HK (1) HK1154793A1 (pt)
HR (1) HRP20150222T1 (pt)
IL (1) IL210134A (pt)
ME (1) ME02147B (pt)
MX (1) MX2011000054A (pt)
MY (1) MY158428A (pt)
NZ (1) NZ590288A (pt)
PE (1) PE20110330A1 (pt)
PL (1) PL2315581T3 (pt)
PT (1) PT2315581E (pt)
RS (1) RS53887B1 (pt)
SI (1) SI2315581T1 (pt)
TW (1) TWI433692B (pt)
UA (1) UA101044C2 (pt)
WO (1) WO2010003568A1 (pt)
ZA (1) ZA201100653B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004144A (es) * 2009-10-08 2012-05-08 Msd Consumer Care Inc Composicion de bajo contenido de eter y aparato de administracion.
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
WO2013088376A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited Gel compositions
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
RU2017106013A (ru) 2014-07-31 2018-08-28 Сан Фармасьютикал Индастриз Лимитед Фармацевтическая композиция изотретиноина для перорального приема
ES2970434T3 (es) 2014-09-12 2024-05-28 Union Therapeutics As Uso antibacteriano de salicilanilidas halogenadas
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CA2986295C (en) 2015-07-10 2023-01-03 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
IL269182B2 (en) 2017-03-10 2023-11-01 Athenex Inc Methods for the treatment and/or prevention of actinic radiation
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US20220175769A1 (en) * 2020-12-08 2022-06-09 Ankh Life Sciences Limited Method of treatment of actinic keratoses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
EP1210937A3 (en) * 1996-06-20 2003-02-05 Lavipharm S.A. Device for topical treatment of acne and its method of manufacture
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
JP2007503428A (ja) * 2003-08-25 2007-02-22 フォーミックス エルティーディー． 浸透性医薬発泡剤
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
CA2570599C (en) * 2004-06-24 2012-03-27 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
RS50693B (sr) * 2005-06-14 2010-06-30 Uni-Pharma Kleon Tsetis Pharmaceutical Stabilni farmaceutski gel diklofenak natrijuma
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
MY158428A (en) 2016-10-14
EA019533B1 (ru) 2014-04-30
AU2009267471B2 (en) 2014-06-05
WO2010003568A8 (en) 2011-02-03
ZA201100653B (en) 2011-10-26
CN102088957A (zh) 2011-06-08
HRP20150222T1 (hr) 2015-05-22
JP2015038129A (ja) 2015-02-26
CY1116111T1 (el) 2017-02-08
TWI433692B (zh) 2014-04-11
PT2315581E (pt) 2015-04-02
WO2010003568A1 (en) 2010-01-14
TW201006507A (en) 2010-02-16
EP2315581A1 (en) 2011-05-04
IL210134A0 (en) 2011-02-28
CO6351710A2 (es) 2011-12-20
KR20110027838A (ko) 2011-03-16
JP5654987B2 (ja) 2015-01-14
JP2011526934A (ja) 2011-10-20
PE20110330A1 (es) 2011-06-11
KR101689898B1 (ko) 2016-12-26
UA101044C2 (ru) 2013-02-25
EA201100020A1 (ru) 2011-06-30
HK1154793A1 (en) 2012-05-04
AU2009267471A1 (en) 2010-01-14
EP2315581B1 (en) 2014-12-17
BRPI0915439B1 (pt) 2019-10-08
CN104825384A (zh) 2015-08-12
ECSP11010762A (es) 2012-03-30
IL210134A (en) 2015-06-30
ME02147B (me) 2015-10-20
US8569320B2 (en) 2013-10-29
NZ590288A (en) 2012-08-31
BRPI0915439B8 (pt) 2021-05-25
PL2315581T3 (pl) 2015-06-30
RS53887B1 (en) 2015-08-31
US20110301130A1 (en) 2011-12-08
ES2532948T3 (es) 2015-04-06
DK2315581T3 (en) 2015-03-23
CL2010001642A1 (es) 2011-04-08
AR072685A1 (es) 2010-09-15
SI2315581T1 (sl) 2015-05-29
EP2143421A1 (en) 2010-01-13
MX2011000054A (es) 2011-11-04
CA2729974A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
BRPI0917675A2 (pt) compostos orgânicos para cura de ferida
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
EP2244709A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
BRPI0813670A2 (pt) Compostos para tratamento
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
BRPI0921679A2 (pt) composto útil para tratar celulite
BR112012015447A2 (pt) composição tópica para aplicação cutânea
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0917552A2 (pt) kit para o tratamento de onicomicose
BRPI0912890A2 (pt) composição farmacêutica para o tratamento de ejaculação precoce
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
BRPI0810762A2 (pt) Composição para tratamento da água
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0915927A2 (pt) uso de inibiodores de hdac para o tratamento da doença de hodgkin

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF